Lindsay Androski compensation by year
Arbutus Biopharma Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $437,750 |
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $714,751 |
| Non-equity incentive | $216,512 |
| Pension and deferred compensation | $0 |
| All other | $0 |
| Total | $1,369,013 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Arbutus Biopharma Corp DEF 14A filed April 14, 2026, accession 0001140361-26-014623, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Arbutus Biopharma Corp filed document, accession 0001140361-26-014623. Every figure is read from that document and cited to the page and table it appears in. Filed April 14, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 310,422 | — | $3.20 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Arbutus Biopharma Corp's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
6 Form 4 lines since the FY2025 proxy (filed April 14, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-01 | Disposition to the issuer | — | 24,655 | $5.00 | 47,682 |
| 2026-09-18 | Exercise or conversion derivative | — | 10,456 | $0.00 | 61,244 |
| 2026-09-18 | Exercise or conversion | — | 116,408 | $3.20 | 144,408 |
| 2026-09-18 | Exercise or conversion derivative | — | 116,408 | $0.00 | 194,014 |
| 2026-09-18 | Exercise or conversion | — | 10,456 | $4.39 | 154,864 |
| 2026-09-18 | Tax withholding | — | 82,527 | $5.07 | 72,337 |
The 6 most recent of 6 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Arbutus Biopharma’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Michael McElhaugh | Former Interim President and Chief Executive Officer | $3,578,150 |
| Tuan Nguyen | Chief Financial Officer | $2,416,995 |
| David Hastings | Former Chief Financial Officer | $2,218,362 |
| Lindsay Androski · this page | President and Chief Executive Officer | $1,369,013 |
Board service
Arbutus Biopharma board · FY2024–FY2025How this board is paid
Company policy: Arbutus Biopharma pays directors a $40,000 cash retainer. As stated in Arbutus Biopharma's FY2025 proxy.
The full Arbutus Biopharma compensation record
free company briefThis page is one person within Arbutus Biopharma's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Arbutus Biopharma's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Arbutus Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order ABUS
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.